Muhammad Aqib Faizan: The Role of Novel Anticoagulants Factor XI/XIa Inhibitors in the Atrial Fibrillation Population
Muhammad Aqib Faizan, Clinical Intern at District Headquarter Hospital, MTI, DIKhan, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
”New study
I had the privilege of leading this study regarding the role of novel anticoagulants FactorXI/XIa inhibitors in atrial fibrillation population (high-thromboembolic-risk patients (mean CHA2DS2-VASc scores 3.9-5.0).
The findings offer a compelling trade-off.
- Significantly lower risk of bleeding across all doses
- Fourfold rise in ischemic stroke
- No significant difference in cardiovascular death, all-cause mortality, or major adverse events indicates general tolerance and neutrality in survival outcomes.
This profile may offer a lifeline for high-risk patients-those in whom bleeding concerns limit traditional anticoagulation.
But the fourfold increase in ischemic stroke is a critical signal.
Proud of what this team accomplished. Huge thanks to Tooba Rehman, Zeyad Kholeif, Fatima Saeed, Jibran Ikram, Alina Tanvir, Carlos Alberto E., Saad Ahmed Waqas, and our mentor, Luis Cerna, whose insights made this happen.”
Title: Dose-Response Efficacy and Safety of Factor XI/XIa Inhibitors in Atrial Fibrillation; a Systematic Review and Meta-Analysis With Subgroup Exploration and Trial Sequential Validation
Authors: Muhammad Aqib Faizan, Tooba Rehman, Mrunalini Dandamudi, Jaivardhan A. Menon, Victoria Zecchin Ferrara, Zeyad Kholeif, Alina Tanvir, Fatima Saeed, Jibran Ikram, Moiuz Chaudhri, Carlos Espiche, Main Muhammad Salman Aslam, Zainab Humayun, Ahmad Mustafa Khalid, Saad Ahmad Waqas, Raheel Ahmad, Luis Cerna
Read the Full Article on Clinical Cardiology.

Stay updated with Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines